A federal appeals court on Friday revived a securities fraud suit against Pfizer brought by investors who claim the company hid the truth about the outcome of a clinical study on possible side effects of Celebrex, an arthritis drug. In the suit, investors claim that Pharmacia -- which has since been acquired by Pfizer -- falsely trumpeted the data from the first six months of a study to claim that Celebrex had fewer gastrointestinal side effects than other arthritis drugs.
3rd Circuit Revives Fraud Suit Against Pfizer
The Legal Intelligencer
February 2, 2009